Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV

Koen K.A. Van Rompay, Kristina Abel, Patricia Earl, Pamela A. Kozlowski, Juliet Easlick, Joseph Moore, Linda Buonocore-Buzzelli, Kimberli A. Schmidt, Robert L. Wilson, Ian Simon, Bernard Moss, Nina Rose, John Rose, Marta Marthas

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

In a previously developed infant macaque model mimicking HIV infection by breast-feeding, we demonstrated that intramuscular immunization with recombinant poxvirus vaccines expressing simian immunodeficiency virus (SIV) structural proteins provided partial protection against infection following oral inoculation with virulent SIV. In an attempt to further increase systemic but also local antiviral immune responses at the site of viral entry, we tested the immunogenicity of different orally administered, replicating vaccines. One group of newborn macaques received an oral prime immunization with a recombinant vesicular stomatitis virus expressing SIVmac239 gag, pol and env (VSV-SIVgpe), followed 2 weeks later by an intramuscular boost immunization with MVA-SIV. Another group received two immunizations with live-attenuated SIVmac1A11, administered each time both orally and intravenously. Control animals received mock immunizations or non-SIV VSV and MVA control vectors. Analysis of SIV-specific immune responses in blood and lymphoid tissues at 4 weeks of age demonstrated that both vaccine regimens induced systemic antibody responses and both systemic and local cell-mediated immune responses. The safety and immunogenicity of the VSV-SIVgpe + MVA-SIV immunization regimen described in this report provide the scientific incentive to explore the efficacy of this vaccine regimen against virulent SIV exposure in the infant macaque model.

Original languageEnglish (US)
Pages (from-to)1481-1492
Number of pages12
JournalVaccine
Volume28
Issue number6
DOIs
StatePublished - Feb 10 2010

Keywords

  • HIV
  • Oral
  • Pediatric
  • SIV
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV'. Together they form a unique fingerprint.

  • Cite this

    Van Rompay, K. K. A., Abel, K., Earl, P., Kozlowski, P. A., Easlick, J., Moore, J., Buonocore-Buzzelli, L., Schmidt, K. A., Wilson, R. L., Simon, I., Moss, B., Rose, N., Rose, J., & Marthas, M. (2010). Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine, 28(6), 1481-1492. https://doi.org/10.1016/j.vaccine.2009.11.061